Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7182271

Cc1cc(C)c(C(=O)Pc2ccc(Oc3ccccc3)cc2Oc2ccccc2)c(C)c1.[Li]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRD5A2 P31213 1/20 0.38
▸ IDH1 O75874 1/20 0.38
▸ FFAR1 O14842 3/20 0.37
▸ FFAR4 Q5NUL3 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ GFER P55789 1/20 0.36
▸ AKR1C3 P42330 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ PTGS1 P23219 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ EPHX2 P34913 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182259 0.97 PTGS1 (0.38) SRD5A2IDH1FFAR1FFAR4KDM4E
Lithium SCHEMBL7175882 0.91 MEN1 (0.41) SRD5A2FFAR1FFAR4KDM4EHSD17B10
Lithium SCHEMBL7174872 0.89 RAF1 (0.37) SRD5A2FFAR1FFAR4KDM4EHSD17B10
SCHEMBL7175874 0.89 MEN1 (0.44) SRD5A2FFAR1FFAR4KDM4EHSD17B10
Lithium SCHEMBL7185604 0.88 SRD5A2 (0.36) SRD5A2FFAR1FFAR4KDM4EHSD17B10
SCHEMBL7182604 0.87 PTGS1 (0.40) SRD5A2IDH1FFAR1MAPK14MAPK1
SCHEMBL7174868 0.87 RAF1 (0.37) SRD5A2FFAR1FFAR4KDM4EHSD17B10
SCHEMBL7185593 0.85 PTGS1 (0.36) SRD5A2FFAR1FFAR4KDM4EHSD17B10
Lithium SCHEMBL7175039 0.83 KMT2A (0.38) SRD5A2FFAR1FFAR4AKR1C3PTGS1
Lithium SCHEMBL7179648 0.82 KMT2A (0.44) KDM4EHSD17B10MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SRD5A2 15/4885IDH1 311/4885FFAR1 671/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SRD5A2 29/4885IDH1 413/4885FFAR1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.